Compare Gilead Sciences, Inc. (GILD) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Procter & Gamble Co — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Procter & Gamble Co trades at $150 (market cap $343.34B). The key difference: Procter & Gamble Co is the larger of the two by market cap, and Procter & Gamble Co pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Procter & Gamble Co for 131 Days on average.
| GILD | PG | |
|---|---|---|
Market Cap | $182.09B | $343.34B |
Volume | 4,960,247 | 8,662,344 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $167.18 |
52-Week Low | $116.74 | $138.10 |
Typical Hold Time | 111 Days | 131 Days |
Enterprise Value | $205.15B | $369.18B |
Dividend Yield | 2.23% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $1.88. Strong fundamentals include $84.28B revenue, 18.44% net margin, and robust cash flow generation. Recent developments include a WNBA partnership and a dividend declaration of $1.09 payable in August 2026.
PG offers stable growth with premium valuation metrics (P/E 22.33, P/S 4.11) supported by strong brand equity and dividend consistency. Risks include premium valuation concerns amid modest growth outlook and competitive pressures. Analyst consensus is bullish with a $160.13 price target, though near-term upside may be limited given current price proximity to the lower target range.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
